SNV1521 in Participants With Advanced Solid Tumors
ConditionAdvanced Solid Tumor
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorSynnovation Therapeutics, Inc.
About this trial
This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.
Eligibility criteria
Qualifiers
Advanced or metastatic solid tumor malignancy
Evaluable or Measurable disease (RECIST 1.1 Criteria).
ECOG Performance Status 0 or 1.
Life expectancy > 3 months
Disqualifiers
History of other malignancy within the past 2 years
Prior diagnosis of Myelodysplastic syndrome or Acute Myeloid Leukemia
Significant cardiovascular disease within 6 months
Significant gastrointestinal disease
Trial design
Treatments tested in this trial
- SNV1521
- DB-1310
- Abiraterone
- Darolutamide
Treatment groups
400 Participants
are divided into 10 treatment groups10
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov